WEST PHARMACEUTICAL (WST) HR chief granted RSUs and stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Favorite Annette F reported acquisition or exercise transactions in this Form 4 filing.

WEST PHARMACEUTICAL SERVICES INC executive Annette F. Favorite, Sr. VP & Chief HR Officer, reported equity awards rather than open-market trades. She received 720 restricted stock units, each representing one share of WST common stock, and 1,712 stock options, all held directly. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Favorite Annette F

Role Sr. VP & Chief HR Officer

Type	Security	Shares	Price	Value
Grant/Award	Rst. Stock Unit	720	$0.00	--
Grant/Award	Stock Option (Right to Buy)	1,712	$0.00	--

Holdings After Transaction: Rst. Stock Unit — 720 shares (Direct); Stock Option (Right to Buy) — 1,712 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of WST common stock. The restricted stock units vest in four equal annual installments beginning on March 1, 2027. The stock option vests in four equal annual installments beginning on March 1, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 11:30 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Favorite Annette F

(Last)

(First)

(Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON

19341

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Sr. VP & Chief HR Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Rst. Stock Unit	⁽¹⁾	03/01/2026		A		720		⁽²⁾	⁽²⁾	Common Stock	720	$0	720	D
Stock Option (Right to Buy)	$254.34	03/01/2026		A		1,712		⁽³⁾	03/01/2036	Common Stock	1,712	$0	1,712	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.

3. The stock option vests in four equal annual installments beginning on March 1, 2027.

	/s/ Caitlin Hippeli, as an agent for Annette Favorite	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Annette F. Favorite report for WEST PHARMACEUTICAL SERVICES INC (WST)?

Annette F. Favorite reported equity awards, not open-market trades. She received 720 restricted stock units and 1,712 stock options, both granted directly to her as part of compensation and reported on a Form 4 insider transaction filing.

How many restricted stock units did Annette F. Favorite receive in this WST Form 4?

Annette F. Favorite received 720 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of WEST PHARMACEUTICAL SERVICES INC common stock, subject to the vesting schedule beginning on March 1, 2027.

How many stock options were granted to Annette F. Favorite by WEST PHARMACEUTICAL SERVICES INC?

She was granted 1,712 stock options described as a “Stock Option (Right to Buy).” These options are held directly and were reported as an acquisition through a grant or award on the Form 4 insider filing.

What is the vesting schedule for Annette F. Favorite’s restricted stock units at WST?

The 720 restricted stock units vest in four equal annual installments. Vesting begins on March 1, 2027, meaning one quarter of the award becomes earned each year over a four-year period, assuming continued eligibility under the award terms.

When do Annette F. Favorite’s WEST PHARMACEUTICAL stock options begin vesting?

The 1,712 stock options vest in four equal annual installments. Vesting starts on March 1, 2027, so one quarter of the option grant becomes exercisable each year over four years, following the same schedule as the restricted stock units.

Did Annette F. Favorite buy or sell WEST PHARMACEUTICAL (WST) shares on the market?

The Form 4 shows no open-market buys or sells. Instead, it reports the acquisition of 720 restricted stock units and 1,712 stock options as grants or awards, which are typical components of executive equity compensation.